KOD Stock Overview
A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kodiak Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.19 |
| 52 Week High | US$7.77 |
| 52 Week Low | US$2.19 |
| Beta | 2.25 |
| 11 Month Change | 65.51% |
| 3 Month Change | 111.99% |
| 1 Year Change | 131.84% |
| 33 Year Change | -93.44% |
| 5 Year Change | -79.09% |
| Change since IPO | -39.07% |
Recent News & Updates
Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)
Nov 15We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Aug 02
Recent updates
Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)
Nov 15We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Aug 02We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Apr 17We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Dec 29We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate
Sep 09Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?
May 26We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Jan 04Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation
Sep 25GreenWood Investors - Kodiak Sciences: The Busted Biotech World
Aug 25Kodiak Sciences FQ1 2022 Earnings Preview
Aug 07Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?
May 18Kodiak Sciences: Potential For Comeback After Trial Setback
May 17Kodiak Sciences: KSI-301 Disappoints
Feb 25Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter
Feb 15We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely
Jan 24Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation
Oct 11Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company
Jul 19Kodiak Sciences EPS in-line
May 10Kodiak Sciences hits the capital raise button; shares dip after hours
Nov 16Kodiak Sciences EPS misses by $0.12
Nov 09Shareholder Returns
| KOD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 11.9% | 2.5% | 2.2% |
| 1Y | 131.8% | 16.1% | 31.6% |
Return vs Industry: KOD exceeded the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: KOD exceeded the US Market which returned 31.7% over the past year.
Price Volatility
| KOD volatility | |
|---|---|
| KOD Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KOD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KOD's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 108 | Victor Perlroth | kodiak.com |
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company’s preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions.
Kodiak Sciences Inc. Fundamentals Summary
| KOD fundamental statistics | |
|---|---|
| Market cap | US$324.98m |
| Earnings (TTM) | -US$191.62m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs KOD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KOD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$191.62m |
| Earnings | -US$191.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.65 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KOD perform over the long term?
See historical performance and comparison